Personalized mRNA vaccine induces strong, durable immunity in hard-to-treat breast cancer

In an experimental trial, a personalized mRNA vaccine was tested in 14 individuals with an aggressive form of breast cancer. It trained immune cells to target cancer-specific mutant proteins, inducing strong, lasting immunity. Ten participants remained disease-free. Analysis of relapses revealed resistance mechanisms, offering essential insights for future therapies. T cells targeting cancer-specific mutant proteins remained in treated individuals years after vaccination.